TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RenovoRx ( (RNXT) ) has provided an update.
On November 14, 2025, RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to issue and sell up to $3,723,029 in shares of its common stock. This agreement, which involves at-the-market offerings or negotiated transactions, is part of RenovoRx’s strategy to leverage its shelf registration statement, extending its ability to raise capital and potentially impacting its market positioning by enhancing financial flexibility.
The most recent analyst rating on (RNXT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
RenovoRx, Inc. operates in the healthcare industry, focusing on innovative therapies and delivery systems for cancer treatment. The company is known for its specialized products aimed at improving the efficacy and safety of cancer therapies, with a market focus on enhancing patient outcomes.
Average Trading Volume: 568,355
Technical Sentiment Signal: Sell
Current Market Cap: $36.65M
For an in-depth examination of RNXT stock, go to TipRanks’ Overview page.